Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?
dc.contributor.author | Tuon F.F. | |
dc.contributor.author | Rymsza A.M. | |
dc.contributor.author | Penteado-Filho S.R. | |
dc.contributor.author | Pilonetto M. | |
dc.contributor.author | Arend L.N. | |
dc.contributor.author | Levin A.S. | |
dc.date.accessioned | 2024-03-13T01:11:40Z | |
dc.date.available | 2024-03-13T01:11:40Z | |
dc.date.issued | 2011 | |
dc.description.firstpage | 246 | |
dc.description.issuenumber | 3 | |
dc.description.lastpage | 249 | |
dc.description.volume | 62 | |
dc.identifier.doi | 10.1016/j.jinf.2011.01.005 | |
dc.identifier.issn | 0163-4453 | |
dc.identifier.uri | https://dspace.mackenzie.br/handle/10899/37009 | |
dc.relation.ispartof | Journal of Infection | |
dc.rights | Acesso Restrito | |
dc.title | Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter? | |
dc.type | Carta ao editor | |
local.scopus.citations | 12 | |
local.scopus.eid | 2-s2.0-79952196433 | |
local.scopus.updated | 2024-05-01 | |
local.scopus.url | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79952196433&origin=inward |